MAIA Biotechnology, Inc.

AMEX: MAIA · Healthcare · Biotechnology

PublicHQ Chicago, IL · CookCIK 0001878313Reports USD

#1161 of 1,418 Healthcare companies by revenue

EA Score

34D

FH 31DQ 39GM —SS 35

v0.1 · 55/100 weight · provisional

↑ Altman-Z, filing timeliness · ↓ return on equity, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$22.4M

Employees

as of 2026-08-18

Market cap

$84.2M

as of 2026-08-18

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02024

Net income-$22.4M-$22.4M2025

Operating income-$24.3M-$24.3M2025

Total assets$9.7M$9.7M2025

Liabilities$7.3M$7.3M2025

Equity$2.4M$2.4M2025

Revenue trend

FY2022 – FY2024 · USD

FY22

FY23

FY24

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is MAIA Biotechnology, Inc.’s revenue?

MAIA Biotechnology, Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Parabilis Medicines, Inc.——Revium Recovery Inc.——HST Global, Inc.——vTv Therapeutics Inc.57C Annovis Bio, Inc.32D Pliant Therapeutics, Inc.48D

Neighbors

Cook →

McDonald's Corporation$26.9B81B+CME Group Inc.$6.5B79B+Illinois Tool Works Inc.$16.0B85A Mondelez International, Inc.$38.5B81B+Motorola Solutions, Inc.$11.7B83B+The Allstate Corporation$67.7B84B+

Key facts

CEOVlad Vitoc

SectorHealthcare

IndustryBiotechnology

HeadquartersChicago, IL

ExchangeAMEX: MAIA

Employees13

IPO date2022-07-28

Latest filings

10-Q2026-08-10 8-K2026-05-22 8-K2026-05-14 10-Q2026-05-11 8-K2026-04-16 8-K2026-04-08 DEF 14A2026-04-07 8-K2026-04-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.